Legal & General Group PLC Abb Vie Inc. Transaction History

Legal & General Group PLC

$420 Billion
Q1 2024

A detailed history of Legal & General Group PLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 15,143,241 shares of ABBV stock, worth $2.44 Billion. This represents 0.66% of its overall portfolio holdings.

Number of Shares

15,143,241

Previous 15,213,521 0.46%

Holding current value

$2.44 Billion

Previous $2.36 Billion 16.96%

% of portfolio

0.66%

Previous 0.61%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$159.82 - $182.1 $11.2 Million - $12.8 Million	-70,280 Reduced 0.46%	15,143,241 $2.76 Billion
Q4 2023 Feb 15, 2024	BUY	$137.6 - $154.97 $429 Million - $483 Million	3,118,987 Added 25.79%	15,213,521 $2.36 Billion
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $71.2 Million - $82.4 Million	-533,050 Reduced 4.22%	12,094,534 $1.8 Billion
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $98.2 Million - $122 Million	741,031 Added 6.23%	12,627,584 $1.7 Billion
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $21.5 Million - $24.7 Million	148,488 Added 1.27%	11,886,553 $1.89 Billion

Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $73.7 Million - $88.4 Million	-533,001 Reduced 4.34%	11,738,065 $1.9 Billion
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $34.8 Million - $39.9 Million	-259,294 Reduced 2.07%	12,271,066 $1.65 Billion
Q2 2022 Aug 22, 2022	BUY	$137.62 - $174.96 $65.5 Million - $83.3 Million	476,257 Added 3.95%	12,530,360 $1.92 Billion
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $104 Million - $128 Million	784,446 Added 6.96%	12,054,103 $1.95 Billion
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $40.1 Million - $50.7 Million	-373,125 Reduced 3.2%	11,269,657 $1.53 Billion
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $49.3 Million - $56 Million	463,730 Added 4.15%	11,642,782 $1.26 Billion
Q2 2021 Aug 12, 2021	BUY	$105.21 - $117.21 $20.3 Million - $22.6 Million	193,109 Added 1.76%	11,179,052 $1.26 Billion
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $30.1 Million - $33.2 Million	-294,397 Reduced 2.61%	10,985,943 $1.19 Billion
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $36.4 Million - $49.1 Million	451,897 Added 4.17%	11,280,340 $1.21 Billion
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $27.5 Million - $32.2 Million	-319,749 Reduced 2.87%	10,828,443 $948 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $129 Million - $172 Million	1,755,024 Added 18.68%	11,148,192 $1.09 Billion
Q1 2020 May 14, 2020	BUY	$64.5 - $97.79 $16 Million - $24.2 Million	247,883 Added 2.71%	9,393,168 $716 Million
Q4 2019 Feb 13, 2020	BUY	$72.13 - $90.25 $13.4 Million - $16.7 Million	185,411 Added 2.07%	9,145,285 $810 Million
Q3 2019 Nov 13, 2019	BUY	$62.98 - $75.72 $6.68 Million - $8.03 Million	106,093 Added 1.2%	8,959,874 $678 Million
Q2 2019 Aug 14, 2019	SELL	$65.7 - $83.98 $7.85 Million - $10 Million	-119,553 Reduced 1.33%	8,853,781 $644 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $122 Million - $144 Million	1,586,937 Added 21.48%	8,973,334 $723 Million
Q4 2018 Feb 15, 2019	BUY	$77.85 - $96.01 $38.2 Million - $47.1 Million	490,348 Added 7.11%	7,386,397 $681 Million
Q3 2018 Nov 20, 2018	SELL	$88.91 - $98.84 $14 Million - $15.6 Million	-157,621 Reduced 2.23%	6,896,049 $652 Million
Q2 2018 Aug 10, 2018	SELL	$89.78 - $106.23 $49.2 Million - $58.2 Million	-548,337 Reduced 7.21%	7,053,670 $654 Million
Q1 2018 May 17, 2018	SELL	$92.01 - $123.21 $42.4 Million - $56.8 Million	-461,143 Reduced 5.72%	7,602,007 $720 Million
Q4 2017 Feb 13, 2018	BUY	$89.56 - $98.21 $722 Million - $792 Million	8,063,150	8,063,150 $780 Million

Others Institutions Holding ABBV

# of Institutions

3,643

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $285B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Abb Vie Inc. Transaction History